See more : Bloomin’ Brands, Inc. (BLMN) Income Statement Analysis – Financial Results
Complete financial analysis of BioNexus Gene Lab Corp. (BGLC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioNexus Gene Lab Corp., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- RIAS A/S (RIAS-B.CO) Income Statement Analysis – Financial Results
- AXP Energy Limited (AXP.AX) Income Statement Analysis – Financial Results
- Titaanium Ten Enterprise Limited (TITAANIUM.BO) Income Statement Analysis – Financial Results
- Gowing Bros. Limited (GOW.AX) Income Statement Analysis – Financial Results
- FreightCar America, Inc. (RAIL) Income Statement Analysis – Financial Results
BioNexus Gene Lab Corp. (BGLC)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.bionexusgenelab.com
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.77M | 10.93M | 13.36M | 11.39M | 126.96K | 212.33K | 107.68K | 0.00 |
| Cost of Revenue | 8.44M | 9.67M | 11.17M | 9.67M | 71.07K | 183.56K | 28.87K | 0.00 |
| Gross Profit | 1.33M | 1.26M | 2.19M | 1.72M | 55.89K | 28.77K | 78.81K | 0.00 |
| Gross Profit Ratio | 13.61% | 11.52% | 16.42% | 15.10% | 44.02% | 13.55% | 73.19% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.41M | 1.73M | 1.20M | 1.33M | 356.64K | 241.93K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.41M | 1.73M | 1.20M | 1.33M | 356.64K | 241.93K | 206.72K | 835.00 |
| Other Expenses | -486.04K | -179.28K | -66.49K | -886.94K | -25.05K | 273.07K | 0.00 | 0.00 |
| Operating Expenses | 3.92M | 1.55M | 1.14M | 446.00K | 331.59K | -31.14K | 206.72K | 835.00 |
| Cost & Expenses | 12.36M | 11.22M | 12.31M | 10.12M | 402.66K | 152.43K | 235.59K | 835.00 |
| Interest Income | 0.00 | 12.48K | 12.97K | 11.31K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.93K | 12.48K | 12.97K | 11.31K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 108.42K | 105.42K | 108.22K | 101.60K | 53.33K | 40.61K | 15.03K | 835.00 |
| EBITDA | -2.49M | -185.76K | 1.16M | 1.38M | -222.37K | 100.51K | -104.38K | 0.00 |
| EBITDA Ratio | -25.43% | -1.70% | 8.71% | 12.08% | -175.16% | 47.34% | -104.83% | 0.00% |
| Operating Income | -2.59M | -291.18K | 1.06M | 1.27M | -275.71K | 59.90K | -127.91K | -840.00 |
| Operating Income Ratio | -26.54% | -2.66% | 7.90% | 11.18% | -217.17% | 28.21% | -118.79% | 0.00% |
| Total Other Income/Expenses | -13.93K | -12.48K | -12.97K | -11.31K | 0.00 | 0.00 | 0.00 | 5.00 |
| Income Before Tax | -2.61M | -303.66K | 1.04M | 1.26M | -275.71K | 59.90K | -119.41K | -835.00 |
| Income Before Tax Ratio | -26.69% | -2.78% | 7.80% | 11.08% | -217.17% | 28.21% | -110.90% | 0.00% |
| Income Tax Expense | 21.53K | 52.31K | 291.28K | 168.41K | -29.24K | 33.45K | 4.34K | -835.00 |
| Net Income | -2.63M | -355.97K | 751.57K | 1.09M | -246.47K | 26.45K | -123.75K | -835.00 |
| Net Income Ratio | -26.91% | -3.26% | 5.62% | 9.61% | -194.14% | 12.46% | -114.92% | 0.00% |
| EPS | -0.17 | -0.02 | 0.05 | 0.13 | -0.03 | 0.00 | -0.02 | 0.00 |
| EPS Diluted | -0.17 | -0.02 | 0.05 | 0.13 | -0.03 | 0.00 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 15.88M | 14.41M | 14.27M | 8.58M | 7.20M | 5.53M | 6.22M | 6.22M |
| Weighted Avg Shares Out (Dil) | 15.88M | 14.41M | 14.27M | 8.58M | 7.20M | 5.53M | 6.22M | 6.22M |
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.
KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn.
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that its wholly owned subsidiary, MRNA Scientific Sdn. Bhd. (“MRNA...
BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
KUALA LUMPUR, Malaysia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing of a strategic partnership Memorandum of Understanding (MOU)...
BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production
KUALA LUMPUR, Malaysia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, the “Company”), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), has invested approximately RM 2...
BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia...
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation...
Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today?
BioNexus Gene Lab (NASDAQ: BGLC ) stock is falling on Friday but investors will note that this comes after its shares underwent a rally late on Thursday. BioNexus Gene Lab shares closed out Thursday up 28.8% with about 3.1 million units...
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare
KUALA LUMPUR, Malaysia, April 19, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corporation (NASDAQ: BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation...
Why Is BioNexus (BGLC) Stock Up 323% Today?
BioNexus (NASDAQ: BGLC ) stock is rocketing higher on Tuesday despite a lack of news concerning the chemical raw material products company. Instead, traders are seeing shares of BGLC stock rally this morning alongside heavy trading.
Why Is BioNexus Gene Lab (BGLC) Stock Up 33% Today?
BioNexus Gene Lab (NASDAQ: BGLC ) stock is rising higher on Wednesday despite a lack of news concerning the chemical raw material company. There haven't been any new press releases that explain why BGLC stock is up today.
Source: https://incomestatements.info
Category: Stock Reports